LONDON, 21 September 2026. Vantage Biosciences, a clinical-stage company developing oral therapies for diabetes-associated vision loss, today announced participation in the following ophthalmology conferences in Europe and the United States in the fourth quarter of 2026.

Upcoming conferences

•     26th EURETINA Congress: 1-4 October 2026, VIECON Vienna Congress & Convention Center, Vienna, Austria

•     Eyecelerator@AAO 2026: 8 October 2026, NewOrleans, Louisiana, USA

•     American Academy of Ophthalmology (AAO 2026): 9-12 October, New Orleans, Louisiana, USA

•     FLORetina-ICOOR 2026: 3-6 December 2026, Fortezza da Basso, Florence, Italy

Vantage is developing oruvestat (VX-01), an investigational, orally administered inhibitor of amine oxidase copper containing 3 (AOC3), for non-proliferative diabetic retinopathy (NPDR), for which there is no approved non-invasive treatment. The Phase 2 SeeClear study (VX01-DR-201) of oruvestat in patients with moderate-to-severe NPDR is fully enrolled across 26 sites in the United States,Australia and Southeast Asia, with topline data anticipated in Q4 2027.

“There is a clear need for a well-tolerated oral treatment that can be started earlier inthe disease course and delivered in routine practice, and the SeeClear study is designed to evaluate whether oral AOC3 inhibition can address that need. We look forward to sharing exciting updates from our programme with the industry.” said Theo Empeslidis, Medical Director of Vantage Biosciences.

About Vantage Biosciences

Vantage Biosciences is a clinical-stage company developing oral therapies for diabetes-associated vision loss. Its lead programme, oruvestat (VX-01), is an investigational, orally administered small-molecule inhibitor of AOC3, a dual-function enzyme that contributes to leukocyte adhesion and oxidative stress in the retinal microvasculature and is implicated in the inflammation and neurovascular dysfunction that characterise diabetic retinopathy. Oruvestat is being evaluated in SeeClear (VX01-DR-201), a randomised, double-masked,placebo-controlled Phase 2 study in patients with moderate-to-severe non-proliferative diabetic retinopathy at 26 sites in the United States,Australia and Southeast Asia (ClinicalTrials.gov identifier NCT06770933). The company is headquartered at 78 Pall Mall, London SW1Y 5ES, United Kingdom. Further information is available at www.vantage-biosciences.com.

Media enquiries

Vantage Biosciences

enquiries@vantage-biosciences.com

‍